These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment. Scheyer A; Yasmin F; Naskar S; Patel S Neuropsychopharmacology; 2023 Jan; 48(1):37-53. PubMed ID: 36100658 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research. Galaj E; Hempel B; Moore A; Klein B; Bi GH; Gardner EL; Seltzman HH; Xi ZX Transl Psychiatry; 2022 Jul; 12(1):286. PubMed ID: 35851573 [TBL] [Abstract][Full Text] [Related]
5. β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly He XH; Galaj E; Bi GH; He Y; Hempel B; Wang YL; Gardner EL; Xi ZX Front Pharmacol; 2021; 12():722476. PubMed ID: 34566647 [TBL] [Abstract][Full Text] [Related]
6. The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area. Zhang H; Lipinski AA; Liktor-Busa E; Smith AF; Moutal A; Khanna R; Langlais PR; Largent-Milnes TM; Vanderah TW Front Pharmacol; 2021; 12():632757. PubMed ID: 33953672 [TBL] [Abstract][Full Text] [Related]
7. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. Chalhoub RM; Kalivas PW Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315 [TBL] [Abstract][Full Text] [Related]
8. Cannabinoid CB He XH; Jordan CJ; Vemuri K; Bi GH; Zhan J; Gardner EL; Makriyannis A; Wang YL; Xi ZX Acta Pharmacol Sin; 2019 Mar; 40(3):365-373. PubMed ID: 29967454 [TBL] [Abstract][Full Text] [Related]
9. Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling. Wenzel JM; Cheer JF Neuropsychopharmacology; 2018 Jan; 43(1):103-115. PubMed ID: 28653666 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Flores A; Maldonado R; Berrendero F Front Neurosci; 2013 Dec; 7():256. PubMed ID: 24391536 [TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid signaling in neurotoxicity and neuroprotection. Pope C; Mechoulam R; Parsons L Neurotoxicology; 2010 Sep; 31(5):562-71. PubMed ID: 19969019 [TBL] [Abstract][Full Text] [Related]
12. A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. Orio L; Edwards S; George O; Parsons LH; Koob GF J Neurosci; 2009 Apr; 29(15):4846-57. PubMed ID: 19369553 [TBL] [Abstract][Full Text] [Related]
13. Role of endocannabinoids in regulating drug dependence. Parolaro D; Vigano D; Realini N; Rubino T Neuropsychiatr Dis Treat; 2007 Dec; 3(6):711-21. PubMed ID: 19300605 [TBL] [Abstract][Full Text] [Related]
14. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Huestis MA; Boyd SJ; Heishman SJ; Preston KL; Bonnet D; Le Fur G; Gorelick DA Psychopharmacology (Berl); 2007 Nov; 194(4):505-15. PubMed ID: 17619859 [TBL] [Abstract][Full Text] [Related]
15. The endocannabinoid system as an emerging target of pharmacotherapy. Pacher P; Bátkai S; Kunos G Pharmacol Rev; 2006 Sep; 58(3):389-462. PubMed ID: 16968947 [TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Navarro M; Carrera MR; Del Arco I; Trigo JM; Koob GF; Rodríguez de Fonseca F Eur J Pharmacol; 2004 Oct; 501(1-3):235-7. PubMed ID: 15464083 [TBL] [Abstract][Full Text] [Related]
17. Functional interaction between opioid and cannabinoid receptors in drug self-administration. Navarro M; Carrera MR; Fratta W; Valverde O; Cossu G; Fattore L; Chowen JA; Gomez R; del Arco I; Villanua MA; Maldonado R; Koob GF; Rodriguez de Fonseca F J Neurosci; 2001 Jul; 21(14):5344-50. PubMed ID: 11438610 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266 [TBL] [Abstract][Full Text] [Related]
19. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305 [TBL] [Abstract][Full Text] [Related]